Stock Market Update - March 11, 2026
Today's stock market saw some significant movers. Here's a breakdown of 5 stocks that caught our attention:
1. ACXP - Acurx Pharmaceuticals, Inc.
Price: $6.03 | Change: +107.93% ($3.13)
ACXP surged an impressive 107.93% after Acurx Pharmaceuticals announced exciting developments for its lead antibiotic candidate, ibezapolstat. The stock gained momentum around March 12, 2026, primarily due to the initiation of a new pilot clinical trial for patients suffering from multiply-recurrent Clostridioides difficile infection (rCDI), with the first patient expected to be dosed in late 2026.
This investor enthusiasm is further fueled by the drug's readiness to advance into international Phase 3 clinical trials for the general C. difficile infection (CDI) population, backed by highly positive Phase 2 results that showed a 96% clinical cure rate and no recurrences. Ibezapolstat stands out as it has the potential to be a first-in-class treatment that not only cures CDI but also prevents recurrence by sparing beneficial gut bacteria, a significant advantage over many current broad-spectrum antibiotics. The prospect of such an innovative treatment moving into late-stage development is driving the excitement.
2. SAFX - XCF Global, Inc. Class A Common Stock
Price: $0.4982 | Change: +74.50% ($0.2127)
SAFX just experienced an impressive 74.50% gain, largely fueled by a significant shareholder decision and a substantial capital raise. On March 6, XCF Global's stockholders approved issuing new shares to a single investor, EEME Energy SPV I LLC. This crucial approval unlocked a $10 million investment from EEME, with the funds primarily earmarked to develop the company's Reno facility and boost its production of Sustainable Aviation Fuel (SAF).
The initial $3.8 million of the investment has already been received, with the remaining $6.2 million expected in phases this month. This capital injection isn't just about one facility; it's part of a broader proposed business combination involving XCF Global and other renewables companies. The overarching goal is to advance the decarbonization of the aviation industry, making this stock movement particularly interesting for those watching the green energy sector.
3. SXTP - 60 Degrees Pharmaceuticals, Inc.
Price: $3.22 | Change: +71.28% ($1.34)
SXTP shot up an impressive 71.28% after 60 Degrees Pharmaceuticals, Inc. announced highly positive clinical trial results on March 11, 2026. Their tafenoquine treatment demonstrated a 100% cure rate in all three patients enrolled in an expanded-use trial for relapsing babesiosis.
This open-label study, building on earlier research from 2024, evaluated tafenoquine in immunosuppressed patients who had previously failed conventional treatments. The combined data from seven patients now suggests a near 100% cure rate when weekly tafenoquine is added to existing regimens.
What makes this particularly significant is that babesiosis is a serious, tick-borne illness with no FDA-approved treatment, posing a life-threatening risk, especially to vulnerable individuals. While tafenoquine is currently approved for malaria prevention, these promising results have led 60 Degrees Pharmaceuticals to believe existing babesiosis treatment guidelines should be reviewed for this potential new use.
4. PAVS - Paranovus Entertainment Technology Ltd.
Price: $2.28 | Change: +65.22% ($0.9)
PAVS:NASDAQ just posted an impressive 65.22% gain, catching the eye of many investors around March 12, 2026. This significant jump in Paranovus Entertainment Technology Ltd. stock is primarily fueled by two major pieces of news that have boosted market confidence.
First, the company successfully regained compliance with Nasdaq’s minimum bid price requirement in January 2026, averting a delisting threat. This crucial step secured its spot on the Nasdaq Capital Market, removing a big cloud of uncertainty for shareholders. Adding to the positive sentiment, PAVS reported an extraordinary 18,037% year-over-year revenue increase for the six months ended September 30, 2025, reaching $12.41 million. This growth, driven by its U.S. e-commerce and TikTok-related service units, also saw the company return to profitability with a net profit of $97,708.
What makes this move particularly interesting is the one-two punch of regaining stability through Nasdaq compliance and demonstrating explosive financial growth with a return to profit. This powerful combination has clearly resonated with investors, driving the stock's remarkable upward momentum.
5. ASNS - Actelis Networks, Inc.
Price: $0.555 | Change: +47.57% ($0.1789)
ASNS surged an impressive 47.57% around March 12, 2026, driven by news of a substantial order from a Japanese governmental entity. Actelis Networks announced a contract to supply dozens of its MetaLight networking units. These systems are designed to provide robust, secure connectivity for critical civil and defense infrastructure modernization projects across Japan, including transportation, utilities, and public safety.
The appeal of MetaLight technology lies in its ability to deliver fiber-grade speeds and security over existing copper wiring, offering a rapid and cost-effective solution compared to extensive new fiber installations. This strategic order aligns well with Japan's "Digital Infrastructure Development Plan for 2030," which prioritizes upgrading national digital infrastructure and security.
Adding to the positive sentiment, Actelis also secured a significant $120 million order from the California Department of Transportation (Caltrans) for a highway modernization project. These major contract wins collectively highlight the growing demand for Actelis' specialized networking solutions in government and public agency sectors.
This analysis was generated using AI and real-time stock data. Always do your own research before making investment decisions.